Bristol Myers Squibb Reports Three-Year CheckMate-648 Data for Opdivo in Esophageal Cancer

Bristol Myers Squibb today presented three-year overall survival data from the Phase 3 CheckMate-648 trial evaluating Opdivo (nivolumab) plus chemotherapy or Opdivo plus Yervoy (ipilimumab) versus chemotherapy in patients with previously untreated advanced esophageal squamous cell carcinoma. The data showed that the overall survival benefits of both Opdivo combinations were maintained at three years.